` ALVR (Allovir Inc) vs S&P 500 Comparison - Alpha Spread

ALVR
vs
S&P 500

Over the past 12 months, ALVR has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's 12% growth.

Stocks Performance
ALVR vs S&P 500

Loading

Performance Gap
ALVR vs S&P 500

Loading
ALVR
S&P 500
Difference

Performance By Year
ALVR vs S&P 500

Loading
ALVR
S&P 500
Add Stock

Competitors Performance
Allovir Inc vs Peers

S&P 500
ALVR
ABBV
AMGN
GILD
VRTX
Add Stock

Allovir Inc
Glance View

Market Cap
35.1m USD
Industry
Biotechnology

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

ALVR Intrinsic Value
38.66 USD
Undervaluation 70%
Intrinsic Value
Price
Back to Top